Maxcyte (MXCT) Receivables (2020 - 2026)

Maxcyte (MXCT) has 7 years of Receivables data on file, last reported at $4.2 million in Q1 2026.

• Quarterly Receivables fell 23.15% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (down 23.15% YoY) and the FY2025 annual result came in at $3.5 million, down 25.18% from the prior year.
• Receivables grew to $4.2 million in Q1 2026 per MXCT's latest filing, from $3.5 million in the prior quarter.
• Across five years, Receivables topped out at $11.2 million in Q4 2022 and bottomed at $3.5 million in Q4 2025.
• The 5-year median for Receivables is $6.0 million (2024), against an average of $6.6 million.
• The widest annual swing landed in 2023, when Receivables tumbled 48.3%; it then jumped 82.15% in 2025.
• Tracing MXCT's Receivables over 5 years: stood at $11.2 million in 2022, then slumped by 48.3% to $5.8 million in 2023, then slipped by 18.97% to $4.7 million in 2024, then slipped by 25.18% to $3.5 million in 2025, then increased by 21.21% to $4.2 million in 2026.
• Per Business Quant, the three latest MXCT Receivables figures stand at $4.2 million (Q1 2026), $3.5 million (Q4 2025), and $8.3 million (Q3 2025).

Peer Comparison